Jinwei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinwei Li has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Jieruo Gu
Shenzhen Longhua Institute of Immunology Transformation Shenzhen China
3 shared publications- Xianghui Wen
Shenzhen Longhua District Central Hospital Shenzhen China
3 shared publications Budian Liu
The Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou China
2 shared publicationsLiuzhong Zhou
Shenzhen Huishan Biotechnology co., Ltd. Shenzhen China
2 shared publications- Xiqing Luo
Department of Rheumatology and Immunology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
2 shared publications - An‐Ping Huo
Institute of Medicine Chung Shan Medical University Taichung Taiwan
1 shared publication
Latest Publications
- 22 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70822
Human Umbilical Cord Mesenchymal Stem Cells Alleviate Autoimmune POI Associated With Downregulated UBE2N ‐Mediated Ovarian Inflammation
Objective: To evaluate the therapeutic efficacy of human umbilical cord‐derived mesenchymal stem cells (hUC‐MSCs) in a murine model of autoimmune premature ovarian insufficiency (POI), and to investigate the association between ubiquitin‐conjugating enzyme E2N (UBE2N) expression and disease progression as well as treatment response. Methods: Autoimmune POI was induced in female BALB/c mice by zona pellucida glycoprotein 3 peptide (pZP3) immunization. Thirty mice were randomly assigned to Control, POI Model, and hUC‐MSC Treatment groups. Treated mice received weekly tail vein injections of hUC‐MSCs (1 × 10 6 cells/mouse) for 4 weeks. Estrous cyclicity, fertility, ovarian histopathology, peripheral Th17/Treg balance, and the expression of IL‐17, IFN‐γ, and UBE2N were evaluated by immunohistochemistry. Results: Compared with the POI Model group, hUC‐MSC treatment restored regular estrous cyclicity, improved ovarian morphology, and increased litter size. Flow cytometry showed correction of the abnormal Th17/Treg imbalance in treated mice. Immunohistochemistry revealed marked upregulation of UBE2N, IL‐17, and IFN‐γ in ovarian tissue from POI mice, whereas hUC‐MSC administration significantly reduced their expression. No treatment‐related adverse effects were observed. Conclusion: hUC‐MSCs effectively alleviated ovarian dysfunction in autoimmune POI mice. The therapeutic improvement was accompanied by systemic immune rebalancing and decreased aberrant ovarian UBE2N expression, indicating UBE2N as a candidate inflammatory biomarker associated with autoimmune ovarian injury and immune dysregulation.
- 22 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70822
Human Umbilical Cord Mesenchymal Stem Cells Alleviate Autoimmune POI Associated With Downregulated UBE2N ‐Mediated Ovarian Inflammation
Objective: To evaluate the therapeutic efficacy of human umbilical cord‐derived mesenchymal stem cells (hUC‐MSCs) in a murine model of autoimmune premature ovarian insufficiency (POI), and to investigate the association between ubiquitin‐conjugating enzyme E2N (UBE2N) expression and disease progression as well as treatment response. Methods: Autoimmune POI was induced in female BALB/c mice by zona pellucida glycoprotein 3 peptide (pZP3) immunization. Thirty mice were randomly assigned to Control, POI Model, and hUC‐MSC Treatment groups. Treated mice received weekly tail vein injections of hUC‐MSCs (1 × 10 6 cells/mouse) for 4 weeks. Estrous cyclicity, fertility, ovarian histopathology, peripheral Th17/Treg balance, and the expression of IL‐17, IFN‐γ, and UBE2N were evaluated by immunohistochemistry. Results: Compared with the POI Model group, hUC‐MSC treatment restored regular estrous cyclicity, improved ovarian morphology, and increased litter size. Flow cytometry showed correction of the abnormal Th17/Treg imbalance in treated mice. Immunohistochemistry revealed marked upregulation of UBE2N, IL‐17, and IFN‐γ in ovarian tissue from POI mice, whereas hUC‐MSC administration significantly reduced their expression. No treatment‐related adverse effects were observed. Conclusion: hUC‐MSCs effectively alleviated ovarian dysfunction in autoimmune POI mice. The therapeutic improvement was accompanied by systemic immune rebalancing and decreased aberrant ovarian UBE2N expression, indicating UBE2N as a candidate inflammatory biomarker associated with autoimmune ovarian injury and immune dysregulation.
- 21 July 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (7) , e70311
Noncanonical Differentiation of Memory B Cells Drives Latent Tuberculosis Infection Reactivation Upon Tumor Necrosis Factor‐Alpha Inhibitor Therapy: An Integrative Transcriptomic Study
Aim: Tumor necrosis factor inhibitors (TNFi) are widely used for the treatment of autoimmune diseases, with latent tuberculosis infection (LTBI) reactivation being a significant unresolved issue. The pathogenic mechanisms are not fully understood. Integrated transcriptomic analysis could provide insights into monitoring tuberculosis progression after TNFi therapy and help reduce LTBI reactivation. Methods: We selected six transcriptomic datasets from studies related to TNFi treatment and tuberculosis. Pathway enrichment, pseudotime, and transcription factor analyses were performed to explore the underlying mechanisms. Results: Our analysis revealed distinct transcriptional changes in memory B cells during tuberculosis progression and TNFi therapy. In active tuberculosis (ATB), ROR1 + memory B cells were identified in a noncanonical differentiation trajectory, characterized by downregulation of B cell‐related genes (e.g., CD22, EBF1, MS4A1), reduced translational capacity, and suppression of immune response pathways, accompanied by upregulation of oxidative phosphorylation, which highlighted metabolic alterations during tuberculosis progression. A similar subtype also emerged in TNFi‐treated patients, suggesting that metabolic reprogramming of memory B cells may disrupt immune balance, thereby contributing to LTBI reactivation and ATB development following TNFi therapy. Conclusions: The study integrates bioinformatics and single‐cell RNA sequencing to reveal the role of memory B cells in ATB progression and TNFi treatment, offering insights into TNFi‐associated TB susceptibility and potential therapeutic targets.
- 21 July 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (7) , e70311
Noncanonical Differentiation of Memory B Cells Drives Latent Tuberculosis Infection Reactivation Upon Tumor Necrosis Factor‐Alpha Inhibitor Therapy: An Integrative Transcriptomic Study
Aim: Tumor necrosis factor inhibitors (TNFi) are widely used for the treatment of autoimmune diseases, with latent tuberculosis infection (LTBI) reactivation being a significant unresolved issue. The pathogenic mechanisms are not fully understood. Integrated transcriptomic analysis could provide insights into monitoring tuberculosis progression after TNFi therapy and help reduce LTBI reactivation. Methods: We selected six transcriptomic datasets from studies related to TNFi treatment and tuberculosis. Pathway enrichment, pseudotime, and transcription factor analyses were performed to explore the underlying mechanisms. Results: Our analysis revealed distinct transcriptional changes in memory B cells during tuberculosis progression and TNFi therapy. In active tuberculosis (ATB), ROR1 + memory B cells were identified in a noncanonical differentiation trajectory, characterized by downregulation of B cell‐related genes (e.g., CD22, EBF1, MS4A1), reduced translational capacity, and suppression of immune response pathways, accompanied by upregulation of oxidative phosphorylation, which highlighted metabolic alterations during tuberculosis progression. A similar subtype also emerged in TNFi‐treated patients, suggesting that metabolic reprogramming of memory B cells may disrupt immune balance, thereby contributing to LTBI reactivation and ATB development following TNFi therapy. Conclusions: The study integrates bioinformatics and single‐cell RNA sequencing to reveal the role of memory B cells in ATB progression and TNFi treatment, offering insights into TNFi‐associated TB susceptibility and potential therapeutic targets.
- 24 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70299
Causal Relationship of Immune Cells and Metabolites in Ankylosing Spondylitis: A Mendelian Randomization Analysis
Objective: This study aims to analyze the immune metabolism mechanism of Ankylosing Spondylitis (AS) and explain the causal relationship between immune cells and metabolites in the progression of AS disease through Mendelian randomization (MR) analysis, providing a theoretical basis for targeted therapy. Methods: The causal relationship between 486 metabolites and 731 immunophenotypes and AS was evaluated by the two‐step MR method, and key mediating variables were screened. Results: Univariate MR identified 42 immunophenotypes and 8 metabolites that were significantly associated with the risk of AS. Two‐step MR showed that the proportion of CD33dim HLA DR+ CD11b− %CD33dim HLA DR+ cells decreased, the secretion level of betaine increased, and the risk of AS increased significantly. Conclusion: It was found that immune cells CD33dim HLA DR+ CD11b− %CD33dim HLA DR+ and its metabolite betaine have a causal relationship with the occurrence and development of AS, which is worth verifying in the clinical diagnosis and treatment of AS.
- 24 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70299
Causal Relationship of Immune Cells and Metabolites in Ankylosing Spondylitis: A Mendelian Randomization Analysis
Objective: This study aims to analyze the immune metabolism mechanism of Ankylosing Spondylitis (AS) and explain the causal relationship between immune cells and metabolites in the progression of AS disease through Mendelian randomization (MR) analysis, providing a theoretical basis for targeted therapy. Methods: The causal relationship between 486 metabolites and 731 immunophenotypes and AS was evaluated by the two‐step MR method, and key mediating variables were screened. Results: Univariate MR identified 42 immunophenotypes and 8 metabolites that were significantly associated with the risk of AS. Two‐step MR showed that the proportion of CD33dim HLA DR+ CD11b− %CD33dim HLA DR+ cells decreased, the secretion level of betaine increased, and the risk of AS increased significantly. Conclusion: It was found that immune cells CD33dim HLA DR+ CD11b− %CD33dim HLA DR+ and its metabolite betaine have a causal relationship with the occurrence and development of AS, which is worth verifying in the clinical diagnosis and treatment of AS.